Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A first Phase 2b study to investigate the safety and efficacy of the optimal dose range of PQ912 in early AD patients

Trial Profile

A first Phase 2b study to investigate the safety and efficacy of the optimal dose range of PQ912 in early AD patients

Planning
Phase of Trial: Phase II

Latest Information Update: 29 Nov 2018

At a glance

  • Drugs PQ 912 (Primary)
  • Indications Alzheimer's disease
  • Focus Proof of concept; Therapeutic Use
  • Acronyms SAPHIR 2
  • Most Recent Events

    • 29 Nov 2018 According to a Probiodrug media release, presented the detailed study design of the Phase 2b core program of PQ-912 which incorporated the newest FDA and EMA draft guidance for early AD trials.
    • 23 Apr 2018 According to a Probiodrug media release, clinical trial design of phase 2b was chosen specifically to make use of newly issued FDA draft guidelines for Alzheimer's, which, with good results, may open an avenue to Phase 2b conditional approval.
    • 30 Nov 2017 According to a Probiodrug media release, preparations of the trial have been initiated.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top